A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Carpten, J. D., Faber, A. L., Horn, C. L., Donoho, G. P., Briggs, S., Robbins, C. M., Hostetter, G. H., Boguslawski, S. J., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,322

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. (2004) · Nature Cell Biology · doi:10.1038/nature02371 · Cited by 1,080

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma

Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date

Criscitiello, C., Viale, G., Curigliano, G., & Goldhirsch, A. (2018) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s134641 · Cited by 26

Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women

Khan, F. A., Esnakula, A. K., Ricks‐Santi, L. J., Zafar, R., KANAAN, Y. M., & Naab, T. J. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.03.020 · Cited by 26

The lncRNA SEMA3B‐AS1/HMGB1/FBXW7 Axis Mediates the Peritoneal Metastasis of Gastric Cancer by Regulating BGN Protein Ubiquitination

Huang, G., Xiang, Z., Wu, H., He, Q., Dou, R., Yang, C., Song, J., Huang, S., Wang, S., & Xiong, B. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5055684 · Cited by 26

HER2 Directed Therapy for Gastric/Esophageal Cancers

Won, E. S., Janjigian, Y. Y., & Ilson, D. H. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0292-6 · Cited by 25

Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells

Kim, H. J., Kim, H., Yoon, Y., Kim, M.-S., Lee, G.-S., Han, S., Im, S., Kim, T., Oh, D., & Bang, Y. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834e7d9b · Cited by 25

Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance

Nahta, R. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/648965 · Cited by 25

Cross-talk and modulation of signaling between somatostatin and growth factor receptors

Kumar, U. (2011) · Endocrine · doi:10.1007/s12020-011-9524-8 · Cited by 25

Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy

Zhou, Y., Wang, C., Zhu, H., Lin, Y., Pan, B., Zhang, X., Huang, X., Xu, Q., Xu, Y., & Sun, Q. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158143 · Cited by 25

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

Filipits, M., Dafni, U. G., Gnant, M., Polydoropoulou, V., Hills, M., Kiermaier, A. C., de Azambuja, E., Larsimont, D., Rojo, F., Viale, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3473 · Cited by 25

Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma

Gambardella, V., Fleitas, T., Tarazona, N., Cejalvo, J. M., Gimeno-Valiente, F., Martínez‐Ciarpaglini, C., Huerta, M., Roselló, S., Castillo, J., Roda, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz143 · Cited by 25

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer

Korkola, J. E., Collisson, E. A., Heiser, L. M., Oates, C. J., Bayani, N., Itani, S. M., Esch, A. M., Thompson, W., Griffith, O. L., Wang, N. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133219 · Cited by 25

Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial

Huang, L., Chen, S., Yang, W., Xu, B., Huang, T., Yang, H., Zheng, H. Y., Wang, Y., Song, E., Zhang, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4337 · Cited by 23

Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients

Tessari, A., Cosimo, S. D., & Palmieri, D. (2013) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s53304 · Cited by 26

Everolimus: a new hope for patients with breast cancer

Şendur, M. A. N., Zengin, N., Aksoy, S., & Altundağ, K. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.846253 · Cited by 25

Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors

CARLSSON, J., SHEN, L., XIANG, J., Xu, J., & Wei, Q. (2012) · Oncology Letters · doi:10.3892/ol.2012.996 · Cited by 25

The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced Breast Cancer

Gnant, M. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0277-1 · Cited by 25

Target Points in Trastuzumab Resistance

Shojaei, S., Gardaneh, M., & Shamabadi, A. R. (2012) · International Journal of Breast Cancer · doi:10.1155/2012/761917 · Cited by 25

Buparlisib in breast cancer.

Sirohi, B., Rastogi, S., & Dawood, S. (2015) · Future Oncology · doi:10.2217/fon.15.56 · Cited by 26

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells

Lyu, H., Yang, X. H., Edgerton, S. M., Thor, A. D., Wu, X., He, Z., & Liu, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6404 · Cited by 25

Genomic Dysregulation in gastric tumors

Janjigian, Y. Y., & Kelsen, D. P. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23263 · Cited by 24

Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

Takada, M., Higuchi, T., Tozuka, K., Takei, H., Haruta, M., Watanabe, J. A., Kasai, F., Inoue, K., Kurosumi, M., Miyazaki, M., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-241 · Cited by 24

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy

Tharin, Z., Richard, C., Dérangère, V., Ilie, A., Arnould, L., Ghiringhelli, F., Boidot, R., & Ladoire, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-31593-w · Cited by 24

Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer

Li, J., Goh, E. L. K., He, J., Li, Y., Fan, Z., Yu, Z., Yuan, P., & Liu, D. (2023) · Biology · doi:10.3390/biology12050697 · Cited by 27

AXL – a new player in resistance to HER2 blockade

Adam‐Artigues, A., Arenas, E. J., Arribas, J., Prat, A., & Cejalvo, J. M. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102639 · Cited by 24

The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review

Fulton-Ward, T., & Middleton, G. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.124 · Cited by 23

Intracellular antigens as targets for antibody based immunotherapy of malignant diseases

Wang, Y., Wang, X., Ferrone, C. R., Schwab, J. H., & Ferrone, S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.019 · Cited by 24

Regulation of HER2 Oncogene Transcription by a Multifunctional Coactivator/Corepressor Complex

Garee, J. P., Chien, C. D., Li, J. V., Wellstein, A., & Riegel, A. T. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1379 · Cited by 24

A gene expression profile indicative of early stage HER2 targeted therapy response

O’Neill, F., Madden, S. F., CLYNES, M. M., Crown, J. P., Doolan, P., Aherne, S. T., & O'Connor, R. A. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-69 · Cited by 24

Inhibition of autophagy induced by PTEN loss promotes intrinsic breast cancer resistance to trastuzumab therapy

Liao, N., Guo-chun, Z., An, S., Li, X., Wang, K., Jian, Z., Chong-Yang, R., Wen, L., & Lv, H. (2015) · Tumor Biology · doi:10.1007/s13277-015-4392-0 · Cited by 24

p110α Inhibition Overcomes Stromal Cell–Mediated Ibrutinib Resistance in Mantle Cell Lymphoma

Guan, J., Huang, D., Yakimchuk, K., & Okret, S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0784 · Cited by 25

Current Development of Monoclonal Antibodies in Cancer Therapy

Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 25

Systematic exploration of cancer‐associated microRNA through functional screening assays

Izumiya, M., Tsuchiya, N., Okamoto, K., & Nakagama, H. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02007.x · Cited by 24

Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer

Swanton, C., Szállási, Z., Brenton, J. D., & Downward, J. (2008) · Breast Cancer Research · doi:10.1186/bcr2159 · Cited by 24

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., Alwahsh, M., Lambert, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02578-w · Cited by 23

Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial

Yan, H., Yu, K., Zhang, K., Liu, L., & Li, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.22270 · Cited by 23

Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis

Raphael, J., Desautels, D. N., Pritchard, K. I., Petkova, E., & Shah, P. S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.010 · Cited by 24

Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer

Sang, X., Li, L., Rui, C., Liu, Y., Liu, Z., Tao, Z., Cheng, H.-L. M., & Liu, P. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.011 · Cited by 23

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

Doi, T., Tamura, K., Tanabe, Y., Yonemori, K., Yoshino, T., Fuse, N., Kodaira, M., Bando, H., Noguchi, K., Shimamoto, T., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2810-z · Cited by 23

Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer

Peddi, P. F., Shatsky, R. A., & Hurvitz, S. A. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.08.004 · Cited by 23

Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition

Goltsov, A., Faratian, D., Langdon, S. P., Bown, J., Goryanin, I., & Harrison, D. J. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.011 · Cited by 24

Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling

Kharmate, G., Rajput, P. S., Watt, H. L., Somvanshi, R. K., Chaudhari, N., Qiu, X., & Kumar, U. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.006 · Cited by 23

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer

Tanioka, M., Sakai, K., Sudo, T., Sakuma, T., Kajimoto, K., Hirokaga, K., Takao, S., Negoro, S., Minami, H., Nakagawa, K., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3121-5 · Cited by 23

Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy

Guiu, S., Mouret‐Reynier, M., Touré, M., & Coudert, B. P. (2013) · Journal of Oncology · doi:10.1155/2013/854121 · Cited by 23

Validation of a Phosphoprotein Array Assay for Characterization of Human Tyrosine Kinase Receptor Downstream Signaling in Breast Cancer

Chergui, F., Chrétien, A.-S., Bouali, S., Ramacci, C., Rouyer, M., Bastogne, T., Génin, P., Leroux, A., & Merlin, J. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.116632 · Cited by 23

CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer

Agostinetto, E., Debien, V., Marta, G. N., Lambertini, M., Piccart, M. J., & de Azambuja, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13535 · Cited by 24

The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy

Gámez‐Pozo, A., Carrión, R. M. P., Manso, L., Crespo, C., Mendiola, C., López‐Vacas, R., Berges‐Soria, J., Álvarez, I., Vila, M. M., Calero, J. L. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109611 · Cited by 24

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib

Vogel, C., Chan, A., Gril, B., Kim, S.-B., Kurebayashi, J., Liu, L., Lu, Y., & Moon, H. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq084 · Cited by 23

An emerging toolkit for targeted cancer therapies: Table 1.Preprint

Mills, G. B. (2012) · Genome Research · doi:10.1101/gr.136044.111 · Cited by 23

DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer

Momeny, M., Tienhaara, M., Sharma, M., Chakroborty, D., Varjus, R., Takala, I., Merisaari, J., Padzik, A., Vogt, A., Paatero, I., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00088-0 · Cited by 24

Finding effective cancer therapies through loss of function genetic screens

Bernards, R. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.007 · Cited by 23

Genomic Markers of Resistance to Targeted Treatments in Gastric Cancer: Potential New Treatment Strategies

Raimondi, A., Nichetti, F., Peverelli, G., Bartolomeo, M. D., de Braud, F., & Pietrantonio, F. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0077 · Cited by 22

Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation

Virzì, A., Gentile, A., Benvenuti, S., & Comoglio, P. (2018) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1721147115 · Cited by 19

Use of Liquid Biopsy to Detect PIK3CA Mutation in Metastatic Breast Cancer

Nakai, M., Yamada, T., Sekiya, K., Sato, A., Hankyo, M., Kuriyama, S., Takahashi, G., Kurita, T., Yanagihara, K., Yoshida, H., et al. (2021) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2022_89-107 · Cited by 22

Personalized therapeutic strategies in HER2-driven gastric cancer

Ughetto, S., Migliore, C., Pietrantonio, F., Apicella, M., Petrelli, A., D’Errico, L., Durando, S., Moya‐Rull, D., Bellomo, S. E., Rizzolio, S., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01165-w · Cited by 21

Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment

Samuels, M., Cilibrasi, C., Papanastasopoulos, P., & Giamas, G. (2022) · Biomolecules · doi:10.3390/biom12010132 · Cited by 23

The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis

Mukherjee, A. G., Wanjari, U. R., Bradu, P., Murali, R., Kannampuzha, S., Loganathan, T., Doss, C. G. P., Arun Prakash, B. P., Renu, K., Dey, A., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103757 · Cited by 22

Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process

Deb, T. B., Zuo, A., Barndt, R. J., Sengupta, S., Janković, R., & Johnson, M. D. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3337-z · Cited by 22

Beyond Trastuzumab and Lapatinib: New Options for HER2-Positive Breast Cancer

Zardavas, D., Cameron, D., Krop, I. E., & Piccart, M. J. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e2 · Cited by 22

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

Gullo, G., Bettio, D., Torri, V., Masci, G., Salvini, P., & Santoro, A. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9155-y · Cited by 22

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

Miller, T., & Arteaga, C. (2011) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2011.10.024 · Cited by 24

PIK3CA/AKT1 Mutations in Breast Carcinoma: a Comprehensive Review of Experimental and Clinical Studies

Troxell, M. L. (2012) · Journal of Clinical & Experimental Pathology · doi:10.4172/2161-0681.s1-002 · Cited by 24

PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum

Goel, S., & Krop, I. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw246 · Cited by 22

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Taveira, M. D. O., Nabavi, S., Wang, Y.-K., Tonellato, P. J., Esteva, F. J., Cantley, L. C., & Wulf, G. M. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2358-x · Cited by 22

Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab

Nishimura, R., Toh, U., Tanaka, M., Saimura, M., Okumura, Y., Saito, T., Tanaka, T., Teraoka, M., Shimada, K., Katayama, K., et al. (2017) · Oncology · doi:10.1159/000468521 · Cited by 22

PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer

Agahozo, M. C., Sieuwerts, A. M., Doebar, S. C., Verhoef, E. I., Beaufort, C. M., Ruigrok-Ritstier, K., de Weerd, V., Sleddens, H. F. B. M., Dinjens, W. N. M., Martens, J. W. M., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0019 · Cited by 22

PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction

McLean, B. A., Patel, V. B., Zhabyeyev, P., Chen, X., Basu, R., Wang, F., Shah, S., Vanhaesebroeck, B., & Oudit, G. Y. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010961 · Cited by 22

PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype

Guarneri, V., Dieci, M. V., Bisagni, G., Brandes, A. A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1731 · Cited by 23

Human somatostatin receptor-3 distinctively induces apoptosis in MCF-7 and cell cycle arrest in MDA-MB-231 breast cancer cells

War, S. A., Kim, B., & Kumar, U. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.019 · Cited by 22

Cooperating transcription factors mediate the function of estrogen receptor

Fiorito, E., Katika, M. R., & Hurtado, A. (2012) · Chromosoma · doi:10.1007/s00412-012-0392-7 · Cited by 22

“New” molecular taxonomy in breast cancer

Hergueta‐Redondo, M., Palacios, J., Cano, A., & Moreno‐Bueno, G. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0290-x · Cited by 22

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine

Leone, J. P., Recondo, G., Vega, M., Galanternik, F., Diaz-Canton, E. A., & Leone, B. A. (2016) · Cancer Management and Research · doi:10.2147/cmar.s104447 · Cited by 22

Cardiovascular toxicity of PI3Kα inhibitors

Sadasivan, C., Zhabyeyev, P., Labib, D., White, J. A., Paterson, D. I., & Oudit, G. Y. (2020) · Clinical Science · doi:10.1042/cs20200302 · Cited by 22

PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.

Duman, B. B., Şahin, B., Acikalin, A., Ergin, M., & Zorludemir, S. (2013) · PubMed · Cited by 21

PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy

Fidler, M. J., Morrison, L. E., Basu, S., Buckingham, L. E., Walters, K. S., Batus, M., Jacobson, K., Jewell, S. S., Coon, J., & Bonomi, P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.494 · Cited by 22

Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer

Hurvitz, S. A., & Kakkar (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s29996 · Cited by 21

PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients

Elwy, F., Helwa, R., Leithy, A. A. E., Shehab El din, Z., Assem, M., & Hassan, N. H. A. (2017) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2017.18.1.57 · Cited by 21

Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance

Paddock, M. N., Field, S. J., & Cantley, L. C. (2019) · Journal of Lipid Research · doi:10.1194/jlr.s092130 · Cited by 24

Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO)

Alipour, F., Riyahi, N., Safaroghli‐Azar, A., Sari, S., Zandi, Z., & Bashash, D. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.105615 · Cited by 21

HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer

Zhao, J., Krishnamurti, U., Zhang, C., Meisel, J. L., Wei, Z., Suo, A., Aneja, R., Li, Z., & Li, X. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153155 · Cited by 21

Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines

Jastrzebski, K., Thijssen, B., Kluin, R. J. C., de Lint, K., Majewski, I. J., Beijersbergen, R. L., & Wessels, L. F. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2698 · Cited by 21

Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling

Abramson, V. G., Lloyd, M. C., Ballinger, T. J., Sanders, M. E., Du, L., Lai, D., Su, Z., Mayer, I. A., Levy, M. A., LaFrance, D. R., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2945-3 · Cited by 20

Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy

Faratian, D., Um, I., Wilson, D. S., Mullen, P., Langdon, S. P., & Harrison, D. J. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.014 · Cited by 19

Innovative personalized medicine in gastric cancer: time to move forward

Lee, J., Kim, K. ‐., Kang, W. K., & Ou, S. ‐. I. (2014) · Clinical Genetics · doi:10.1111/cge.12408 · Cited by 20

Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+ breast cancer cells

Murad, R., Avanes, A. A., Ma, X., Geng, S., Mortazavi, A., & Momand, J. A. (2021) · Gene · doi:10.1016/j.gene.2021.145808 · Cited by 20

KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer

Shimozaki, K., Shinozaki, E., Yamamoto, N., Imamura, Y., Osumi, H., Nakayama, I., Wakatsuki, T., Ooki, A., Takahari, D., Ogura, M., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03966-7 · Cited by 20

Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer

Song, X., & Lin, Q. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221090351 · Cited by 23

Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer

Maddox, A. L., Brehove, M. S., Eliato, K. R., Saftics, A., Romano, E., Press, M. F., Mortimer, J. E., Jones, V., Schmolze, D. D., Seewaldt, V. L., et al. (2022) · Cancers · doi:10.3390/cancers14112795 · Cited by 21

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution

Giugliano, F., Schianca, A. C., Corti, C., Ivanova, M. D., Bianco, N., Dellapasqua, S., Criscitiello, C., Fusco, N., Curigliano, G., & Munzone, E. (2023) · Cancers · doi:10.3390/cancers15051385 · Cited by 21

Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer

Cao, Y., Li, Y., Liu, R., Zhou, J., & Wang, K. (2023) · Cancers · doi:10.3390/cancers15092568 · Cited by 22

Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data

Chen, H., Hu, X., Wang, D., Wang, Y., Yu, Y., & Yao, H. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101738 · Cited by 20

Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach

Takada, M., Terunuma, H., Deng, X., Dewan, M. Z., Saji, S., Kuroi, K., Yamamoto, N., & Toi, M. (2010) · Breast Cancer · doi:10.1007/s12282-010-0198-5 · Cited by 20

Pooled RNAi Screens - Technical and Biological Aspects

Boettcher, M., & Hoheisel, J. D. (2010) · Current Genomics · doi:10.2174/138920210791110988 · Cited by 20

Dual HER2 blockade: preclinical and clinical data

Patel, T. A., Dave, B., Rodriguez, A. A., Chang, J. C., Perez, E. A., & Colón‐Otero, G. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0419-5 · Cited by 20

Targeted Therapy in Breast Cancer: Current Status and Future Directions

Mukai, H. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq037 · Cited by 20

Resistance to Targeted Therapies in Breast Cancer

Braga, S. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3347-1_8 · Cited by 21

Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody

Wang, C., Wang, L., Yu, X., Zhang, Y., Meng, Y., Wang, H., Yang, Y., Gao, J., Wei, H., Zhao, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17451 · Cited by 20

Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways

Lackner, M. R. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.78 · Cited by 20

BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors

Zecchin, D., Boscaro, V., Médico, E., Barault, L., Martini, M., Arena, S., Cancelliere, C., Bartolini, A., Crowley, E. H., Bardelli, A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0243 · Cited by 21

DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines

D’Amico, S., Krasnowska, E. K., Manni, I., Toietta, G., Baldari, S., Piaggio, G., Ranalli, M., Gambacurta, A., Vernieri, C., Giacinto, F. D., et al. (2020) · Cells · doi:10.3390/cells9051260 · Cited by 20

A Systems Approach to Analysis of Molecular Complexity in Breast Cancer

Hennessy, B. T., Gonzalez-Angulo, A. M., Carey, M. S., & Mills, G. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2620 · Cited by 20

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

Esteva, F. J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J. S., Sahin, A. A., Hortobagyi, G. N., & Yu, D. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090885 · Cited by 285

PI3 Kinase Activation and Response to Trastuzumab Therapy: What's neu with Herceptin Resistance?

Park, B. H., & Davidson, N. E. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.004 · Cited by 47

An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer

Sueta, A., Yamamoto, Y., Yamamoto‐Ibusuki, M., Hayashi, M., Takeshita, T., Yamamoto, S., & Iwase, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116054 · Cited by 30

An evaluation of PI3K pathway activation on the efficacy of both trastuzumab and lapatinib.

Hu, X., Wang, L. P., Zhang, Q. L., Zhang, J., Guo, H., Sun, S., Wang, B. Y., Jia, Z., Shao, Z. M., & Wang, Z. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.541

Abstract P3-07-11: High activation of PI3K pathway defined by PIK3CA mutation, PTEN, and INPP4B expression are associated with trastuzumab efficacy in HER2-positive breast cancer

Sueta, A., Yamamoto, Y., Takeshita, T., Yamamoto‐Ibusuki, M., & Iwase, H. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p3-07-11